Clinical trials: Bundibugyo Virus Disease
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469
- Trial name
- NCT07737717
- Testing
- mRNA-1469
- Where
- 3 sites in Canada
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Bundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed.
- Trial name
- TUMAINI (NCT07842107)
- Testing
- Candidate BDBV vaccine, Active comparator
- Where
- Democratic Republic of the Congo
- Volunteers
- 3,620 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Filovirus Disease
Study of Filovirus Disease Morbi-mortality
Filoviruses, including Ebola and Marburg, cause hemorrhagic fevers associated with high mortality and still limited scientific literature, in particular for some rare species such as the Bundibugyo virus.
- Trial name
- TEMBO (NCT07821580)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute